Following reviews of case reports and postmarketing adverse event reports, the FDA notified health care professionals of an increased risk of eosinophilic pneumonia in patients treated with Cubicin (daptomycin). The medication is indicated for treatment of serious skin and bloodstream infections. Health care professionals are instructed to carefully monitor patients being treated with Cubicin. Patients receiving the medication should contact their health care professional immediately if symptoms such as new or worsening fever, cough, shortness of breath, or difficulty breathing develop.